Category Press Releases

Greywolf Therapeutics, a clinical-stage biotech company advancing novel antigen modulation technology that controls T cells to guide the immune system, has appointed Darlene Deptula-Hicks as Chief Financial Officer. An accomplished biotech and healthcare executive, Ms. Deptula-Hicks most recently served as…

Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is proud to announce the appointment of Howard Hechler as Chief Executive Officer. The Board of Directors is highly confident in…

Enveda, a biotechnology company using AI to translate nature into new medicines, announced today that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for its first asset targeting atopic dermatitis and other inflammatory…

Kanvas Biosciences, a spatial biology company, has unveiled clinical trial results at the 2024 Society for Immunotherapy of Cancer (SITC) meeting, showing the potential of fecal microbiota transplantation (FMT) in combination with anti-PD-1 re-induction to treat patients with microsatellite instability-high…

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced that it will present new data on a range of B-cell malignancies and treatments at the 66th ASH Annual Meeting in San Diego, December 7-10. The…

Moderna announced that Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older. “This approval demonstrates how our mRNA platform can tackle significant…

AstraZeneca will present new data from its cutting-edge hematology portfolio and pipeline at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from December 7 to 10, 2024. The company will showcase 57 abstracts, featuring 13 approved and…

The recently released Global Tuberculosis Report 2024 provides an updated overview of the challenges and progress in the global fight against tuberculosis (TB) during 2023. TB affected 10.8 million people in 2023, claiming approximately 1.25 million lives, including 161,000 deaths…

Sarepta Therapeutics a leader in precision genetic medicine for rare diseases, has announced its financial results for the third quarter of 2024, showcasing strong revenue growth and significant progress in its portfolio. “We’re pleased to report another strong quarter, with…

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported its financial results for the third quarter ending September 30, 2024. Teva’s President and CEO, Richard Francis, commented, “We’ve achieved our seventh consecutive quarter of growth, with global revenues reaching…

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced the design of a pivotal Phase 3 clinical trial for ION582, an investigational treatment for Angelman syndrome (AS), following successful alignment with the U.S. Food and Drug Administration (FDA). AS is a rare…